Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CETP | P11597 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9302172 | 0.92 | TSHR (0.44) | TSHRNPSR1CETPKCNH2ALDH1A1 | |
| SCHEMBL9858391 | 0.89 | CETP (0.42) | TSHRNPSR1CETPKCNH2 | |
| SCHEMBL8717188 | 0.84 | TSHR (0.41) | TSHRCETPPOLBMAPTMAPK1 | |
| SCHEMBL3586787 | 0.83 | IDO1 (0.40) | TSHRNPSR1POLB | |
| SCHEMBL13537809 | 0.82 | CETP (0.43) | TSHRCETPPOLBMAPTMAPK1 | |
| SCHEMBL20990542 | 0.80 | CETP (0.43) | TSHRNPSR1CETPALDH1A1 | |
| SCHEMBL1238316 | 0.80 | TSHR (0.56) | TSHRNPSR1CETPKCNH2POLB | |
| SCHEMBL4801868 | 0.80 | IDO1 (0.50) | — | |
| SCHEMBL4350991 | 0.79 | TSHR (0.52) | TSHRNPSR1CETPKCNH2POLB | |
| SCHEMBL10442280 | 0.78 | CETP (0.44) | TSHRCETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975911-B2 | Antibacterial compounds and biological applications thereof | MUTABILIS (FR) | 2018-05-22 | — | — | US | disclosed |
| US-9975911-B2 | Antibacterial compounds and biological applications thereof | MUTABILIS (FR) | 2018-05-22 | — | — | US | disclosed |
| CN-107709288-A | Phosphamide derivative and preparation method and application thereof | 四川海思科制药有限公司 | 2018-02-16 | — | — | CN | disclosed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| EP-2912043-B1 | NEW ANTIBACTERIAL COMPOUNDS AND BIOLOGICAL APPLICATIONS THEREOF | MUTABILIS (FR) | 2016-11-30 | — | — | EP | disclosed |
| US-20150291636-A1 | ANTIBACTERIAL COMPOUNDS AND BIOLOGICAL APPLICATIONS THEREOF | LABORATOIRE BIODIM (FR) | 2015-10-15 | — | — | US | disclosed |
| CN-104936966-A | New antibacterial compounds and biological applications thereof | BIODIM LAB | 2015-09-23 | — | — | CN | disclosed |
| EP-2912043-A1 | NEW ANTIBACTERIAL COMPOUNDS AND BIOLOGICAL APPLICATIONS THEREOF | LABORATOIRE BIODIM (FR) | 2015-09-02 | — | — | EP | disclosed |
| WO-2014067904-A1 | NEW ANTIBACTERIAL COMPOUNDS AND BIOLOGICAL APPLICATIONS THEREOF | LABORATOIRE BIODIM (FR) | 2014-05-08 | — | — | WO | disclosed |
| US-20120114974-A1 | ELECTRONIC DEVICES COMPRISING NOVEL PHOSPHONIC ACID SURFACE MODIFIERS | NATIONAL SCIENCE FOUNDATION | 2012-05-10 | — | — | US | disclosed |
| WO-2010115854-A1 | ELECTRONIC DEVICES COMPRISING NOVEL PHOSPHONIC ACID SURFACE MODIFIERS | GEORGIA TECH RESEARCH CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114974-A1 | ELECTRONIC DEVICES COMPRISING NOVEL PHOSPHONIC ACID SURFACE MODIFIERS | EFNA1, PHOSPHO1, EPHA6 | TSHR 4110/4885NPSR1 2421/4885CETP 4728/4885 |
| US-20150291636-A1 | ANTIBACTERIAL COMPOUNDS AND BIOLOGICAL APPLICATIONS THEREOF | C3AR1, CFH, MSR1 | TSHR 792/4885NPSR1 2489/4885CETP 3704/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | TSHR 4782/4885NPSR1 4160/4885CETP 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.